Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03103932 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Biomarker Guided Discharge of Heart Failure Patients

Study acronym: RADAR
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Peter Liu to Ottawa Heart Institute Research Corporation
    • Primary completion date: Apr 2025 to Dec 30, 2026
    • Study completion date: Dec 2025 to Dec 30, 2026
    • Collaborators: 3 to 2
    v11
  2. Primary completion date: Dec 2024 to Apr 2025v10
  3. Primary completion date: Aug 2023 to Dec 2024
    • Study completion date: Dec 2023 to Dec 2025
    v9
  4. Primary completion date: Aug 2022 to Aug 2023
    • Study completion date: Dec 2022 to Dec 2023
    • Site contact updated
    v8
  5. Primary completion date: Dec 2020 to Aug 2022
    • Study completion date: Aug 2021 to Dec 2022
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Site contact updatedv6
  2. Primary completion date: Sep 2018 to Dec 2020
    • Study completion date: Mar 2019 to Aug 2021
    v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 2017 to Aug 26, 2017
    v4
  4. Start date: May 2017 to Jul 2017v3
  5. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-centre, single blind, randomized study. Patients admitted to hospital with acute decompensated heart failure will be randomized to biomarker guided discharge algorithm vs usual care in a 2:1 ratio. NTproBNP and other biomarkers will be measured within 24 hours of admission. The NTproBNP results will be used to further stratify participants randomized to the biomarker guided group into lower and medium to higher risk pathways. Biomarkers will be repeated after 2-3 days and again prior to discharge. Specific care pathways will be followed for each of the lower risk and medium-higher risk groups. Biomarkers will be repeated 30 days post discharge. Participants will be followed with a phone call at 3 months and return for a follow up visit at 6 months post discharge for outcome evaluation.
Trial Details
NCT Number NCT03103932
Lead Sponsor Ottawa Heart Institute Research Corporation
Collaborators: Genome Canada, Roche Diagnostics GmbH
Conditions
(from sponsor)		 Heart Failure; With Decompensation
Related terms Heart Failure
Enrollment 750 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov